Healthcare / Medical DevicesShenzhen
$49.28
-0.47 (-0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 20%
FCF escenarios
weak_data · normalized FCF $83.2M · quality 37.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
30.0x
↑EV/EBITDA
21.0x
↑ROE
14.2%
↑Gross Margin
80.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.6%
FCF CAGR
—
FCF margin
31.5%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $368.8M · net income $113.1M · FCF $116.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $368.8M | $368.8M | $278.4M | $230.9M | $195.3M |
| Net Income | $113.1M | $113.1M | $78.9M | $40.9M | $35.9M |
| EBITDA | $153.7M | $153.7M | $121.2M | $75.6M | $56.9M |
| EPS | 1.69 | 1.69 | 1.20 | 0.62 | 0.54 |
| Gross Margin | 80.2% | 80.2% | 79.3% | 82.0% | 84.0% |
| Operating Margin | 34.4% | 34.4% | 31.2% | 19.6% | 17.0% |
| Net Margin | 30.7% | 30.7% | 28.3% | 17.7% | 18.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.08 | 0.14 |
| Current Ratio | 10.92 | 10.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $116.0M | $116.0M | $83.2M | $67.6M | $-87.6M |
| Returns | |||||
| ROE | 14.2% | 14.2% | 11.3% | 6.4% | 6.0% |
| Valuation | |||||
| P/E | 30.05 | 30.05 | 33.50 | 68.82 | 71.24 |
| EV/EBITDA | 20.98 | 20.98 | 21.33 | 37.58 | 45.58 |
| P/B | 4.13 | 4.13 | 3.78 | 4.42 | 4.24 |
| Growth & Yield | |||||
| Revenue Growth | 32.5% | 32.5% | 20.6% | 18.2% | — |
| EPS Growth | 40.8% | 40.8% | 93.5% | 14.8% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
37.3%
EPS terminal req.
$4.37
Spread vs growth
3.5%
5Y implied EPS CAGR
25.6%
EPS terminal req.
$5.29
Spread vs growth
15.2%
10Y implied EPS CAGR
17.6%
EPS terminal req.
$8.52
Spread vs growth
23.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.4%
Start / end P/E
53.2x → 29.2x
EPS bridge
1.20 → 1.69
Residual
-18.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.